Ribonucleotide reductase as a novel target in liposarcoma
Advanced liposarcoma has low overall response rates to chemotherapy. There is a need for targeted therapy for liposarcoma. Utilizing microarray and RT- PCR data, we found ribonucleotide reductase M2 (RRM2) to be upregulated in our liposarcoma cell lines and tumor samples. Triapine, (3 Aminopyridine-2-carboxaldehyde-thiosemicarbazone) and hydroxyurea are ribonucleotide reductase inhibitors that exhibit antiproliferative activity in epithelial and hematological malignancies. We have an attenuated herpes simplex virus that requires host cell ribonucleotide reductase to replicate. We hypothesize that RRM2 is a novel target for both chemotherapeutic agents and biological viral agents in the treatment of liposarcoma and plan to validate in the laboratory RRM2 as a new target for the treatment of liposarcoma.